Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to characterize the time profile of the decongestant properties of xylometazoline and to investigate its effect on sleep, general well-being and smell/taste.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Ephedrine; Nasal Decongestants; Pseudoephedrine; Xylometazoline

Criteria

Inclusion Criteria:

• Over 18 years

• Have had moderate common cold symptoms for less than 36 hours.

Exclusion Criteria:

• Congested/runny nose for more than two continuous weeks in the previous 12 months

• Deviated septum or nasal polyps

• Recent use of antibiotics

• Recent sinusitis

Other protocol-defined inclusion/exclusion criteria may apply.